Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) Institutional Ownership
CUSIP: 09075V102
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
282
Shares (Excl. Options)
47,893,528
Price
$95.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
- Symbol
- BNTX on Nasdaq
- Shares outstanding
- 239,647,920
- Price per share
- $88.88
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 47,893,528
- Total reported value
- $4,559,336,247
- % of total 13F portfolios
- 0%
- Share change
- -4,544,850
- Value change
- -$440,520,029
- Number of holders
- 282
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BNTX - BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) is tracked under CUSIP 09075V102.
- 282 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 282 to 24 between Q4 2025 and Q1 2026.
- Reported value moved from $4,559,336,247 to $31,702,855.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 282 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 09075V102?
CUSIP 09075V102 identifies BNTX - BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09075V102:
Significant Owners of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Medine GmbH | 18% | $4,386,515,536 | 42,178,034 | Prof. Ugur Sahin, M.D. | 31 Mar 2025 |
As of 31 Dec 2025, 282 institutional investors reported holding 47,893,528 shares of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX). This represents 20% of the company’s total 239,647,920 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 2.5% | 5,933,594 | +8.8% | 0.03% | $564,878,131 |
| T. Rowe Price Investment Management, Inc. | 1.9% | 4,484,599 | -7.2% | 0.27% | $426,934,000 |
| FLOSSBACH VON STORCH SE | 1.8% | 4,196,048 | -0.8% | 1.6% | $399,463,770 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.6% | 3,800,011 | -1.8% | 0.27% | $361,761,047 |
| Dodge & Cox | 1.5% | 3,614,491 | -0.89% | 0.19% | $344,099,543 |
| BNP PARIBAS FINANCIAL MARKETS | 0.66% | 1,578,094 | 0% | 0.1% | $150,234,549 |
| Temasek Holdings (Private) Ltd | 0.63% | 1,506,027 | 0% | 0.46% | $143,373,770 |
| JANE STREET GROUP, LLC | 0.57% | 1,361,221 | +591% | 0.15% | $129,588,239 |
| BAILLIE GIFFORD & CO | 0.52% | 1,244,867 | -84% | 0.1% | $118,511,339 |
| BlackRock, Inc. | 0.48% | 1,152,884 | +51% | 0% | $109,754,540 |
| Capital International Investors | 0.47% | 1,134,941 | -0.01% | 0.02% | $108,046,383 |
| GSK plc | 0.37% | 889,824 | 0% | 11% | $84,711,245 |
| BANK OF AMERICA CORP /DE/ | 0.31% | 736,597 | +28% | 0.01% | $70,124,035 |
| MORGAN STANLEY | 0.28% | 680,669 | +13% | 0% | $64,799,832 |
| CITADEL ADVISORS LLC | 0.28% | 678,175 | +74% | 0.04% | $64,562,260 |
| Candriam S.C.A. | 0.25% | 604,916 | +2.6% | 0.29% | $57,590,455 |
| FRANKLIN RESOURCES INC | 0.24% | 577,900 | -21% | 0.01% | $55,015,819 |
| Long Focus Capital Management, LLC | 0.21% | 507,655 | +28% | 2.5% | $48,328,756 |
| D. E. Shaw & Co., Inc. | 0.2% | 488,552 | 0.04% | $46,510,150 | |
| DekaBank Deutsche Girozentrale | 0.2% | 481,397 | 0% | 0.1% | $46,397,000 |
| TANG CAPITAL MANAGEMENT LLC | 0.2% | 470,000 | +74% | 2.2% | $44,744,000 |
| DEUTSCHE BANK AG\ | 0.19% | 446,283 | +17% | 0.01% | $42,486,142 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.18% | 437,565 | 0.15% | $41,656,188 | |
| VICTORY CAPITAL MANAGEMENT INC | 0.17% | 400,593 | -3.2% | 0.02% | $38,136,454 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 0.17% | 400,382 | -13% | 0.03% | $38,093,046 |
Institutional Holders of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 354,709 | $31,702,855 | -$8,834,847 | $88.88 | 24 |
| 2025 Q4 | 47,893,528 | $4,559,336,247 | -$440,520,029 | $95.20 | 282 |
| 2025 Q3 | 50,481,130 | $4,974,375,396 | -$319,748,638 | $98.62 | 253 |
| 2025 Q2 | 53,756,637 | $5,723,405,583 | +$241,986,249 | $106.47 | 255 |
| 2025 Q1 | 51,766,102 | $4,713,883,792 | +$16,375,983 | $91.06 | 276 |
| 2024 Q4 | 50,762,221 | $5,785,970,647 | +$270,315,091 | $113.95 | 299 |
| 2024 Q3 | 44,146,673 | $5,240,957,854 | +$448,042,220 | $118.77 | 288 |
| 2024 Q2 | 40,965,872 | $3,292,084,415 | -$3,371,001 | $80.36 | 278 |
| 2024 Q1 | 40,861,236 | $3,768,152,227 | +$21,661,779 | $92.25 | 278 |
| 2023 Q4 | 40,542,745 | $4,273,885,983 | +$369,420,974 | $105.54 | 277 |
| 2023 Q3 | 36,919,967 | $4,008,689,944 | -$40,677,233 | $108.64 | 245 |
| 2023 Q2 | 37,381,433 | $4,042,183,779 | -$207,319,966 | $107.93 | 246 |
| 2023 Q1 | 39,079,137 | $4,865,003,807 | -$130,605,071 | $124.57 | 272 |
| 2022 Q4 | 39,706,670 | $5,966,384,929 | +$387,882,980 | $150.22 | 312 |
| 2022 Q3 | 37,131,368 | $5,008,892,299 | +$489,942,648 | $134.88 | 249 |
| 2022 Q2 | 33,416,255 | $4,980,080,985 | -$212,346,370 | $149.10 | 276 |
| 2022 Q1 | 34,519,697 | $5,890,695,868 | -$225,320,254 | $170.56 | 274 |
| 2021 Q4 | 35,195,775 | $9,066,882,359 | -$433,429,701 | $257.80 | 334 |
| 2021 Q3 | 36,667,998 | $10,011,251,135 | +$781,975,407 | $272.99 | 328 |
| 2021 Q2 | 33,709,299 | $7,548,281,316 | +$1,380,454,495 | $223.88 | 275 |
| 2021 Q1 | 29,716,757 | $3,242,039,601 | +$922,839,812 | $109.19 | 213 |
| 2020 Q4 | 20,695,182 | $1,688,417,367 | -$282,174,671 | $81.52 | 183 |
| 2020 Q3 | 24,274,421 | $1,679,824,791 | -$160,429,955 | $69.23 | 144 |
| 2020 Q2 | 26,613,030 | $1,776,088,789 | +$1,335,873,540 | $66.74 | 108 |
| 2020 Q1 | 6,620,182 | $383,744,138 | -$108,916,451 | $58.40 | 36 |
| 2019 Q4 | 8,476,761 | $285,550,000 | +$285,550,000 | $33.88 | 19 |